Total operating profit from continuing operations was GBP 2,141 million compared with GBP 1,081 million in Q2 2022. Cash generated from operations attributable to continuing operations for the quarter was GBP 1,620 million. Emma Walmsley, Chief Executive Officer, GSK: “We have delivered another excellent quarter of performance, with strong sales and earnings growth, notably in HIV and Vaccines, and continued strengthening of the R&D pipeline and product portfolio. The approval of Arexvy, the world’s first RSV vaccine, was an important milestone for us and is at the forefront of a next wave in vaccine innovation for GSK. Completion of the Bellus Health acquisition also strengthened our late-stage respiratory pipeline. Our momentum supports the upgrade we have made to our financial guidance for 2023 and further increases our confidence in delivering longer-term profitable growth for shareholders.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on GSK:
- GSK Pharma put volume heavy and directionally bearish
- GSK announces ViiV’s cabotegravir for HIV prevention gets positive CHMP opinion
- GSK Earnings this Week: How Will it Perform?
- GSK price target lowered to 1,390 GBp from 1,450 GBp at BofA
- Compugen wins on PVRIG European patent opposition pursued by GSK, third party